Skip to Content

Brookline Capital Management analysts cut Moderna, Inc. earnings estimates (NASDAQ:MRNA)

Brookline Capital Management analysts cut Moderna, Inc. earnings estimates (NASDAQ:MRNA)

MRNA is the ticker symbol representing Moderna, Inc. shares (NASDAQ: MRNA). In a report distributed on January 9, Brookline Capital Management lowered their projections for the earnings per share that Moderna will generate during the fiscal year 2022. In contrast to the previous forecast of $21.66 for the value of each claim, L. Cann of Brookline Capital Management anticipates that the actual value of each share will be $20.23 this year. The current consensus estimate for Moderna’s earnings over the entire year is $21.44 per share. The previous projection was $21.40 per share, an increase from that. In the fourth quarter of 2022, Brookline Capital Management anticipated that the earnings per share for Moderna would amount to $3.75.

Recently, mRNA has been the subject of reports written by several other stock research analysts. These reports have been published. Goldman Sachs Group upgraded shares of Moderna from a “buy” rating to a “strong-buy” rating in a research report issued on Thursday, October 13. The brokerage firm also established a price objective of $290.00 for the company’s stock. SVB Leerink upgraded the stock’s rating to “market perform” and increased their price objective for Moderna shares from $101.00 to $102.00 in a research note published on Tuesday, December 13. The target price of $101.00 was initially established as the goal. Cowen lowered their price objective on shares of Moderna, bringing it down from $165.00 to $145.00, and the announcement was made in a research note published on October 20. Morgan Stanley raised their price objective on shares of Moderna on Friday, December 16, announcing that they were doing so in a research note that was made public. The new price objective is $209.00 per share, up from $170.00 per share previously. In addition to that, they provided the company with a rating of “equal weight.” Piper Sandler reassessed their position on Moderna and shifted their rating from “underweight” to “overweight” in a research note published on December 20. They altered the ratings for more than just this one thing. Five equity research analysts have issued a recommendation to purchase company shares, while seven analysts have advised investors to maintain their current company stock holdings. According to Bloomberg, most market analysts currently have the stock rated as “Hold,” and the average price objective that they have set for the store is $192.14 per share.

The stock of Moderna was first offered for sale on Thursday for $186.64, and trading began at that time. Both the price-to-earnings ratio of the company, which is 6.75, and its beta value, which is 1.71, are very high. At the moment, the total value of the company, as measured by its market capitalization, is $71.70 billion. There is a ratio of 0.05 debt to equity, 1.80 quick ratios to the current balance, and 2.10 current ratio to quick ratio. The percentage of debt to equity is meager. The all-time high for Moderna over the past year is $228.50, and the all-time low for Moderna over the past year is $115.03. The moving average price for the company over the past 50 days is $181.26, and the moving average price over the past 200 days is $158.14, respectively.

Moderna’s most recent quarterly earnings report (NASDAQ: MRNA) was made available to the general public on November 3, 2018, a Thursday. The company reported earnings per share of $2.53, which was $0.51 less than the consensus estimate of $3.04 among industry analysts. However, the actual revenue the company brought in for the quarter was $3.36 billion, which is significantly higher than the $3.33 billion analysts predicted it would bring in for the period. In addition, the return on equity for Moderna was 70.03 percent, and the company’s net margin was 55.00 percent of revenue.

Recently, several hedge funds have either increased the amount of mRNA they hold in their portfolios or decreased the amount they were holding previously. Total Clarity Wealth Management Inc. increased its stake in Moderna by approximately $25,000 over the second quarter, bringing the total value of its holdings in the company to almost $70,000 at the end of the period. During the third quarter, Evoke Wealth LLC achieved a 100.8% increase in the proportion of Moderna stock it owns. Evoke Wealth LLC now has 239 shares of the company’s stock, which has a value of $28,000. This is because, during the most recent fiscal quarter, the company purchased an additional 120 shares, bringing the total number of shares held by the company to 249; Guardian Wealth Advisors LLC made a new investment in Moderna during the third quarter, which resulted in a transaction with a total value of approximately $28,000. During the first three months of this year, Oliver Lagore Vanvalin Investment Group established a new holding in Moderna, estimated to be worth roughly $30,000. During the second quarter, FinTrust Capital Advisors LLC saw a 754.5% increase in the size of its holdings in Moderna, bringing the total to a total value of $. The most recent quarter saw FinTrust Capital Advisors LLC acquire 166 additional company shares, bringing their total number of shares owned to 188, with a value of $31,000. This brought the total number of shares held in the company to 188. Of these, 63.11 percent are owned by institutional investors who have purchased large blocks of stock.

In related news, on October 20, the company’s CEO, Stephane Bancel, sold 40,000 of the company’s shares of stock, which was the subject of other recent headlines. A total of $4,833,200.00 was received for the sale of the claims, which works out to a price of $120.83 per share on average. After considering the purchase, the CEO has a total holding in the company that amounts to 5,411,946 shares, which have an approximate value of $653,925,435 at present. Should you follow this link, you will be taken to the SEC filing in which the transaction was discussed in greater detail. In addition, the company’s director, Noubar Afeyan, sold 10,000 shares of the company’s stock on January 4, which brings us to another piece of news about Moderna. The total value of the shares was $1,821,500.00, which works out to an average price of $182.15 per share when divided by the number of shares sold. Following the completion of the transaction, the director now has a total holding of 2,267,209 company shares, each of which is estimated to be worth a total of $412,972,119.35. The transaction was discussed in a document distributed by the SEC and is currently available on the website of the SEC. In addition, on October 20, Stephane Bancel, the company’s Chief Executive Officer, sold 40,000 of the company’s shares of stock. A total of $4,833,200.00 was received for the sale of the claims, which works out to a price of $120.83 per share on average. As a result of the transaction, the CEO now owns 5,411,946 shares of the company’s stock, which have an approximate value of $653,925,435; the disclosure regarding the sale may be found in this section of the website. Corporate insiders were responsible for selling 445,899 company stock during the most recent fiscal quarter, resulting in a total value of $74,472,586. This transaction took place during the most recent fiscal quarter. Insiders collectively own 17.30% of the full company stock.


Leave a comment

Your email address will not be published. Required fields are marked *